Alta Maness, NP
Psychiatric/Mental Health · Hackensack, NJNPI 1639514649
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.0%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 54.6% of the total. 2025 is the largest year on record at $39,104, more than ten times the $396 reported in 2021. Among psychiatric/mental health clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 511 payments — averaging $146.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$41K
- E.r. Squibb & Sons, L.L.C.$13K
- Neurocrine Biosciences, Inc.$9K
- Johnson & Johnson$7K
- Alkermes, Inc.$4K
- Janssen Scientific Affairs, LLC$1K
- plus $437 from 6 others
What the payments were for
- Consulting fees$14,67320%
- Speaking & faculty fees$43,53458%
- Travel & lodging$8,20811%
- Food & beverage$8,48011%
- Education$1980%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 261 | $41,021 |
| E.r. Squibb & Sons, L.L.C. | 42 | $12,987 |
| Neurocrine Biosciences, Inc. | 105 | $8,629 |
| Johnson & Johnson | 15 | $6,533 |
| Alkermes, Inc. | 59 | $4,360 |
| Janssen Scientific Affairs, LLC | 1 | $1,125 |
| Lundbeck LLC | 9 | $134 |
| Otsuka America Pharmaceutical, Inc. | 7 | $129 |
| Sunovion Pharmaceuticals Inc. | 9 | $125 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $20 |
| Boehringer Ingelheim | 1 | $15 |
| Almatica Pharma LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Austedo XR$25,396
- ARISTADA$12,651
- UZEDY$11,286
- INGREZZA$7,739
- INVEGA SUSTENNA$7,392
- INVEGA TRINZA$7,392
- COBENFY$6,766
- ARISTADA INITIO$3,163
- AUSTEDO$1,895
- INVEGA$1,263
- LYBALVI$480
How this compares
$75,092 in reported general payments places this provider in the 95th percentile of 1,212 psychiatric/mental health providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 74 | $616,734 |
| IngrezzaValbenazine Tosylate | 68 | $401,224 |
| AristadaAripiprazole Lauroxil | 30 | $100,304 |
| RexultiBrexpiprazole | 83 | $79,899 |
| Invega SustennaPaliperidone Palmitate | 18 | $64,133 |
| Risperdal ConstaRisperidone Microspheres | 32 | $40,325 |
| UzedyRisperidone | 18 | $39,553 |
| Abilify MaintenaAripiprazole | 13 | $37,319 |
| VraylarCariprazine Hcl | 23 | $32,899 |
| Risperidone ErRisperidone Microspheres | 33 | $32,490 |
| Lurasidone Hcl | 68 | $19,924 |
| Divalproex Sodium ErDivalproex Sodium | 165 | $9,326 |
| Aripiprazole | 190 | $8,050 |
| TrintellixVortioxetine Hydrobromide | 17 | $7,442 |
| Clozapine | 79 | $7,409 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Uzedy | $41,021 | $656,28792 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $8,629 | $401,22468 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $129 | $117,21996 claims |
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $6,533 | $104,45850 claims |
| Alkermes, Inc.Aristada | $4,360 | $100,30430 claims |
| Almatica Pharma LLCSertraline Hcl | $14 | $926141 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,212 psychiatric/mental health providers in New Jersey.
Other psychiatric/mental health in Hackensack
- Ubong UdofiaMarlton$407K
- Anthony DimuraRed Bank$130K
- Amy PinsenNewton$111K
- Aaron SpectorMarlton$100K
- Fiorella ParadisiSparta$84K
- Diane BurtBridgeton$81K
- Laura LeahySewell$41K
- Linda WinfulMontclair$40K
- Marisa SavicOradel$38K
- Tyreasea Johnson MasonHaddon Township$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.